Medical technology company Enovis Corporation (NYSE:ENOV) will be reporting earnings this Thursday before market hours. Here’s what to expect.
Enovis met analysts’ revenue expectations last quarter, reporting revenues of $558.8 million, up 8.3% year on year. It was a slower quarter for the company, with a significant miss of analysts’ full-year EPS guidance estimates and full-year EBITDA guidance missing analysts’ expectations.
Is Enovis a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Enovis’s revenue to grow 5.4% year on year to $553.5 million, slowing from the 22.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.72 per share.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Enovis has missed Wall Street’s revenue estimates twice over the last two years.
Looking at Enovis’s peers in the medical devices & supplies - specialty segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Integer Holdings delivered year-on-year revenue growth of 11.4%, beating analysts’ expectations by 2.6%, and Bausch + Lomb reported revenues up 5.1%, topping estimates by 2.2%. Integer Holdings traded down 6.3% following the results while Bausch + Lomb was also down 7%.
Read our full analysis of Integer Holdings’s results here and Bausch + Lomb’s results here.
Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the medical devices & supplies - specialty stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.1% on average over the last month. Enovis is down 21.3% during the same time and is heading into earnings with an average analyst price target of $56.30 (compared to the current share price of $25.99).
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.